Balance Sheet
Includes Current Assets, Liabilities and Stockholder's Equity
Latest Financial Results
Q1 2025
Quarter Ended Mar 31, 2025
$7.3M
Revenue for the three months ended March 31, 2025, was $7.3 million, compared to $5.7 million for the same period in 2024
$41.1M
As of March 31, 2025, Adaptimmune had cash and cash equivalents of $41.1 million and Total Liquidity2 of $59.6 million, compared to $91.1 million and $151.6 million respectively, as of December 31, 2024
2Total liquidity is a non-GAAP financial measure, which is explained and reconciled to the most directly comparable financial measures prepared in accordance with GAAP below.
Latest Annual Filing
For Fiscal Year Ending Dec 31, 2024
Report Links
For complete information regarding our financials, see our periodic filings